A PHASE 2B, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY TO
EVALUATE THE IMMUNE RESPONSE AND SAFETY OF THE RSVPREF3 OA INVESTIGATIONAL VACCINE IN
ADULTS (¿50 YEARS OF AGE) WHEN ADMINISTERED TO LUNG AND RENAL TRANSPLANT RECIPIENTS
COMPARING 1 VERSUS 2 DOSES AND COMPARED TO HEALTHY CONTROLS (¿50 YEARS OF AGE)
RECEIVING 1 DOSE
- Registry ID
- 219900 (RSV OA=ADJ-023)
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- GLAXOSMITHKLINE INC
- Start date
- 2023-11-22
- Last update
- 2023-06-15
Conditions
- KIDNEY TRANSPLANTATION
- LUNG TRANSPLANT RECIPIENT
Related clinical trials
- A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, RANDOMIZED PHASE 2 TRIAL EVALUATING THE EFFICACY AND SAFETY OF FELZARTAMAB IN RECIPIENTS OF KIDNEY TRANSPLANTS WITH LATE ISOLATED MICROVASCULAR INFLAMMATION (MVI) - (TRANSPIRE0
- A PHASE 2B, NON-RANDOMIZED, CONTROLLED, OPEN-LABEL, EXTENSION STUDY TO EVALUATE
THE PERSISTENCE OF IMMUNE RESPONSE OF THE ADJUVANTED RSVPREF3 VACCINE AND THE
SAFETY AND IMMUNOGENICITY FOLLOWING REVACCINATION IN LUNG AND KIDNEY TRANSPLANT
RECIPIENTS (¿18 YEARS OF AGE)
- SEMAGLUTIDE FOR THE PREVENTION OF POST-TRANSPLANT DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS
- BELUMOSUDIL TO BLOCK CLAD IN HIGH RISK LUNG TRANSPLANT
RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE BLIND,
PLACEBO-CONTROLLED TRIAL
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF RAVULIZUMAB ADMINISTERED INTRAVENOUSLY IN
ADULT PARTICIPANTS AT HIGH RISK OF DELAYED GRAFT FUNCTION AFTER KIDNEY
TRANSPLANTATION
- EVALUATION OF THIOSULFATE IN END STAGE RENAL DISEASE AND KIDNEY
TRANSPLANTATION
View on source registry